On Target Development: Webinar

Specificity screening of biotherapeutics


Ensuring that a novel biotherapeutic is specific to its intended target is undoubtedly advantageous when selecting promising lead candidates, however, it becomes vital when assessing potential safety implications prior to clinical studies.

This webinar provides an overview of the Cell Microarray technology, with a particular focus on specificity/off-target screening.

  • Understand how data generated with Cell Microarray screening is used in lead selection and safety assessment
  • Explore how specificity data supports IND submissions as either an adjunct to, or replacement for, tissue cross reactivity studies
  • Learn more about identifying and mitigating the risk of clinical toxicity caused by off-target effects of monoclonal antibodies.

Featured presentations:

“True specificity is a critical development characteristic in therapeutic antibody development.”

Jonny Finlay, PhD – CEO, UltraHuman Limited

“Off-target Screening: A Pharma Industry Perspective.”

Martin Scott, PhD – Scientific Leader and Associate Fellow, GSK

“Cell Microarray technology in specificity screening.”

Nick Brown, MSc – Retrogenix Limited

Why use Retrogenix?

Our unique Cell Microarray technology identifies primary receptors and any potential secondary targets with a high degree of specificity and sensitivity, providing valuable data that can inform lead selection, assist with safety assessment and support regulatory submissions.

Retrogenix’s specificity data have been readily accepted in applications for clinical trials and marketing approval in the US (FDA), Europe (EMA), China (NMPA) & Japan (PMDA). Further details can be found in our case study using the link below. Or, to ask a question, please get in touch with a member of our team.


Retrogenix data in regulatory submissions

Get In Touch

    We’ve developed a terrific working relationship with the team at Retrogenix and intend to utilize their microarray technology as a standard screen for future targets. Jim and Jo have become trusted collaborators and we appreciate their flexibility and willingness to work with us through some challenging issues. The quality and timeliness of the data and reports are first rate. We’ve come to rely on their results as a dependable means to confirm results from traditional crossreactivity studies and to identify additional potential unexpected interactions.
    Amy Bourdeau, ‎Senior Preclinical Development Coordinator, Bluebird bio
    See Bluebird bio CAR T case study
    Simcere logo
    Aveo Oncology - The Human Response
    Theraclone Sciences
    Bluebird Bio
    The Center for Infectious Disease Research
    Compugen Logo
    Sanofi Logo
    The University of Copenhagen
    Lund University
    NIH - National Institutes of Health
    The University of Pennsylvania
    Scripps Florida - The Scripps Research Institute
    Peptinnovate Ltd - Unlocking Nature's Potential
    The University of Sheffield
    Capella Bioscience Logo
    Unum Theraputics Logo
    Celyad Logo
    Genmab Logo
    Molecular Partners Logo